Treatment Combo Shows ' Clinical Benefit ' in Liver Cancer Trial Treatment Combo Shows ' Clinical Benefit ' in Liver Cancer Trial
The combination of a tyrosine kinase inhibitor with an immune checkpoint inhibitor significantly improved progression-free survival in patients with hepatocellular carcinoma, shows a new study.MDedge News
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Gastroenterology | Hematology | Hepatocellular Carcinoma | Liver | Liver Cancer | Study | Urology & Nephrology